The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors.
Journal
Advances in hematology
ISSN: 1687-9104
Titre abrégé: Adv Hematol
Pays: United States
ID NLM: 101504271
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
08
2019
revised:
13
02
2020
accepted:
04
03
2020
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
14
4
2020
Statut:
epublish
Résumé
Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. Different thrombotic risk scores for patients with essential thrombocythemia have been proposed, but only one of them (the IPSET-t scoring system) takes into account the classical cardiovascular risk factors as one of the scoring items. Currently, in clinical practice, the presence of cardiovascular risk factors in patients with diagnosis of ET rarely determines the decision to initiate cytoreductive therapies. In our study, we compared different risk models to estimate the thrombotic risk of 233 ET patients and the role of specific driver mutations and evaluated the impact that conventional cardiovascular risk factors (hypertension, cigarette smoking, diabetes, obesity, and dyslipidaemia) have on thrombotic risk in patients with ET. Perspective studies conducted on a polycentric large cohort of patients should be conducted to estimate the impact of cardiovascular risk factors in determining thrombosis in ET patients, evaluating the opportunity of initiating a cytoreductive therapy in patients with cardiovascular risk factors, even if classified into low to moderate risk groups according to other scoring systems.
Identifiants
pubmed: 32280344
doi: 10.1155/2020/9124821
pmc: PMC7139859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9124821Informations de copyright
Copyright © 2020 Salvatrice Mancuso et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615
pubmed: 25037629
Am J Hematol. 2019 Jan;94(1):133-143
pubmed: 30281843
Am J Hematol. 2017 Jan;92(1):94-108
pubmed: 27991718
Hematol Oncol. 2019 Oct;37(4):434-437
pubmed: 31465530
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Med Oncol. 2014 Oct;31(10):231
pubmed: 25223529
Blood. 2012 Dec 20;120(26):5128-33; quiz 5252
pubmed: 23033268
Am J Hematol. 2016 Mar;91(3):318-21
pubmed: 26748894
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood Rev. 2005 Sep;19(5):243-52
pubmed: 15963833
J Clin Oncol. 2011 Feb 20;29(6):761-70
pubmed: 21205761
Blood Cancer J. 2017 Dec 27;7(12):662
pubmed: 29282357
Am J Hematol. 2016 Jun;91(4):390-4
pubmed: 26799697
Semin Thromb Hemost. 2006 Apr;32(3):171-3
pubmed: 16673273
Blood. 2011 Jun 2;117(22):5857-9
pubmed: 21490340